Unicycive Therapeutics Inc (UNCY)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.16-2.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · UNCY
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 210.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
UNCY — earnings miss
Dated 2026-05-12
Results of Operations and Financial Conditions. On May 12, 2026, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Why it matters: Progress in clinical trials is key for future growth and funding.
Supportive ifManagement says one clinical trial is moving forward.
Worry ifNo updates or delays in clinical trials are reported.
Why it matters: If healthcare sector growth speeds up, it may help Unicycive's performance. This matters for investor trust.
Supportive ifHealthcare sector revenue growth speeds up to about 10% year over year.
Worry ifHealthcare sector revenue growth keeps slowing down below current levels.
Why it matters: Progress in getting ready for sales shows how well Unicycive can launch OLC if approved. This affects possible revenue.
Supportive ifManagement says they completed key steps to prepare for sales. This is before the FDA decision.
Worry ifManagement says there are delays or problems in getting ready for sales.
Why it matters: New M&A activity could signal growth opportunities for Unicycive. Investors will look for how this impacts future revenue.
Supportive ifA press release talks about the benefits and money details of the M&A activity.
Worry ifNo new announcements or details on the M&A activity in the next quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$252 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $601 loss on $10,000 · 6.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,521 loss on $10,000 · 45.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The FDA's decision on OLC will impact Unicycive's future revenue and market position. Approval could lead to a commercial launch.
Supportive ifFDA approves the NDA for oxylanthanum carbonate (OLC) by the June 29 target date.
Worry ifFDA rejects the NDA for OLC or delays the decision beyond June 29.
Why it matters: Earnings results will provide insight into Unicycive's financial health and cash burn management. A miss could raise concerns.
Watch forQ2 earnings show a reduction in cash burn or improved financial metrics compared to Q1.
Also watch forQ2 earnings show more cash burn or ongoing poor financial results.
Why it matters: Managing cash burn well is key for Unicycive's future. High cash burn may limit future work.
Worry ifManagement says cash burn has dropped a lot compared to earlier quarters.
Less concerning ifCash burn is still high or rising, showing weak financial control.
Why it matters: M&A activity can strengthen Unicycive's position and resources. New deals could signal growth.
Supportive ifThey announce new partnerships or acquisitions. These help the product pipeline.
Worry ifNo new M&A activity or partnerships are announced.